ArticleCurrent medical imaging2025
An Enhanced CT-based Radiomics Model for Predicting the Anaplastic Lymphoma Kinase Mutation Status in Lung Adenocarcinoma.
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiomics to understand pre-treatment tumor biology for resectable non-small cell lung cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to explore the relationship between radiomics features and anaplastic lymphoma kinase (ALK) gene mutation status in lung adenocarcinoma and to develop a radiomics nomogram for preoperative prediction of ALK mutations.
methodsA retrospective analysis was conducted on 210 patients with histologically confirmed lung adenocarcinoma (50 ALK mutation-positive, 160 mutation-negative), divided into training (n=147) and validation (n=63) cohorts (7:3 ratio). Preoperative enhanced CT images were analyzed using ITK-SNAP for region-of-interest delineation, and radiomics features were extracted
resultsNineteen radiomics features were selected to construct the radiomics signature. The signature achieved an AUC of 0.89 (95% CI: 0.84-0.95) in the training set and 0.79 (95% CI: 0.63-0.95) in the validation set. The radiomics nomogram demonstrated superior performance (AUC=0.80, 95% CI: 0.63-0.97) compared to the clinical model alone (AUC=0.66, 95% CI: 0.47-0.85) in the validation set. While the nomogram showed no statistically significant improvement over the radiomics signature alone ( DISCUSSION: The radiomics nomogram integrating clinical and radiomics data demonstrated robust predictive capability for ALK mutations, highlighting the potential of non-invasive CT-based radiomics in guiding personalized treatment. However, the lack of significant difference between the nomogram and radiomics signature alone suggests limited incremental value from clinical variables in this cohort. Limitations include the retrospective design, single-center data, and class imbalance (fewer ALK-positive cases), which may affect generalizability. External validation is warranted to confirm clinical utility.
conclusionThe CT-derived radiomics signature and nomogram show promise for preoperative ALK mutation prediction in lung adenocarcinoma. These tools could enhance clinical decision-making by identifying candidates for targeted therapies, though further validation is needed to optimize their application in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.